Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial
The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Introduction: Ketamine has emerged as a rapid-acting antidepressant. While ongoing treatment can prevent relapse, concerns exist regarding long-term exposure. Objective: We conducted a randomized trial to examine the feasibility and efficacy of cognitive behavioral therapy (CBT) following intravenous ketamine in treatment-resistant depression (TRD). Methods: Subjects with TRD were recruited and treated with 6 intravenous infusions of ketamine over 3 weeks. Subjects who experienced a clinical response (≥50% improvement in depression severity) were then randomized to receiving CBT or treatment as usual (TAU) for an additional 14 weeks, using a sequential treatment model. Results: Of the 42 patients who signed consent, 28 patients achieved a response and were randomized to CBT or TAU. When measured using the Montgomery-Asberg Depression Rating Scale (primary outcome measure), the effect size at the end of the study was moderate (Cohen d = 0.65; 95% CI –0.55 to 1.82), though the group-by-time interaction effect was not significant. There was a significant group-by-time interaction as measured by the Quick Inventory of Depressive Symptomatology (F = 4.58; p = 0.033), favoring a greater sustained improvement in the CBT group. This corresponded to a moderate-to-large effect size of the Cohen d = 0.71 (95% CI –0.30 to 1.70) at the end of the study (14 weeks following the last ketamine infusion). In a subset of patients (N = 20) who underwent cognitive testing using the emotional N-back assessments before and after ketamine, ketamine responders showed improvement in the accuracy of emotional N-back (t[8] = 2.33; p < 0.05) whereas nonresponders did not (t[10] <1; p ns). Conclusions: This proof-of-concept study provides preliminary data indicating that CBT may sustain the antidepressant effects of ketamine in TRD. Further study and optimization of this treatment approach in well-powered clinical trials is recommended.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Another randomized trial (n = 28) found that cognitive behavioral therapy in addition to repeated ketamine infusions (six infusions over three weeks) generated greater sustained improvement than ketamine alone [57].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [57]
In the citing paper
“Moreover, the concomitant administration of ketamine and psychological interventions ('ketamine- as sisted' therapy) is insufficiently character ized and as such cannot be recommended for TRD 202 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [202]
In the citing paper
“Preliminary evidence suggests that CBT may be capable of prolonging the effect observed in adults with TRD who acutely benefited from ketamine treatment 202 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [202]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750
Self-citationNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Individual differences in executive functions are almost entirely genetic in origin.
Friedman, N. P., Miyake, A., Young, S. E., DeFries, J. C., Corley, R. P., & Hewitt, J. K. (2008) · Journal of Experimental Psychology: General · doi:10.1037/0096-3445.137.2.201 · Cited by 1,547
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
TRIVEDI, M. H., RUSH, A. J., IBRAHIM, H. M., CARMODY, T. J., BIGGS, M. M., SUPPES, T., CRISMON, M. L., SHORES-WILSON, K., TOPRAC, M. G., DENNEHY, E. B., et al. (2004) · Psychological Medicine · doi:10.1017/s0033291703001107 · Cited by 968
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786
Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739
Prevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735
Cognitive and behavioural flexibility: Neural mechanisms and clinical considerations
Uddin, L. Q. (2021) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00428-w · Cited by 698
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Fales, C. L., Barch, D. M., Rundle, M. M., Mintun, M. A., Snyder, A. Z., Cohen, J. D., Mathews, J., & Sheline, Y. I. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.06.012 · Cited by 517
Emotion Regulation in Depression: The Role of Biased Cognition and Reduced Cognitive Control
Joormann, J., & Vanderlind, W. M. (2014) · Clinical Psychological Science · doi:10.1177/2167702614536163 · Cited by 353
Self-citationEsketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Self-citationThe Montgomery‐Åsberg Depression Scale: reliability and validity
Davidson, J., Turnbull, C. D., Strickland, R., Miller, R., & Graves, K. (1986) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1986.tb02723.x · Cited by 290
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Will, C. C., Aird, F., & Redei, E. E. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001345 · Cited by 225
Shiroma, P. R., Johns, B., Kuskowski, M., Wels, J., Thuras, P., Albott, C. S., & Lim, K. O. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.036 · Cited by 221
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
Diamond, P. R., Farmery, A. D., Atkinson, S., Haldar, J., Williams, N., Cowen, P. J., Geddes, J. R., & McShane, R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114527361 · Cited by 176
Guidi, J., Tomba, E., & Fava, G. A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040476 · Cited by 167
Chandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
Guidi, J., & Fava, G. A. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3650 · Cited by 155
Shiroma, P. R., Albott, C. S., Johns, B., Thuras, P., Wels, J., & Lim, K. O. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714001011 · Cited by 126
Ketamine accelerates fear extinction via mTORC1 signaling
Girgenti, M. J., Ghosal, S., LoPresto, D., Taylor, J. R., & Duman, R. S. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.12.026 · Cited by 125
Wilkinson, S. T., Wright, D., Fasula, M. K., Fenton, L., Griepp, M., Ostroff, R. B., & Sanacora, G. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000457960 · Cited by 122
Self-citationSanacora, G., Fenton, L. R., Fasula, M. K., Rothman, D. L., Levin, Y., Krystal, J. H., & Mason, G. F. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.07.015 · Cited by 117
Self-citationA Word to the Wise About Intranasal Esketamine
Schatzberg, A. F. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19040423 · Cited by 96
Dozois, D. J. A., & Dobson, K. S. (2001) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.69.6.914 · Cited by 95
Wilkinson, S. T., Holtzheimer, P. E., Gao, S., Kirwin, D. S., & Price, R. B. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.004 · Cited by 95
Self-citationWilkinson, S. T., Katz, R. B., Toprak, M., Webler, R., Ostroff, R. B., & Sanacora, G. (2018) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.17m11731 · Cited by 91
Self-citationYang, Z., Oathes, D. J., Linn, K. A., Bruce, S. E., Satterthwaite, T. D., Cook, P. A., Satchell, E. K., Shou, H., & Sheline, Y. I. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.12.006 · Cited by 83
Jett, J. D., Boley, A. M., Girotti, M., Shah, A., Lodge, D. J., & Morilak, D. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3957-3 · Cited by 75
Metaplastic Effects of Subanesthetic Ketamine on CA1 Hippocampal Function
Izumi, Y., & Zorumski, C. F. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.08.002 · Cited by 63
Kobak, K. A., Williams, J. B. W., Jeglic, E., Salvucci, D., & Sharp, I. R. (2008) · Depression and Anxiety · doi:10.1002/da.20392 · Cited by 50
Patton, M. S., Lodge, D. J., Morilak, D. A., & Girotti, M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.236 · Cited by 44
Can Cognitive Behavioral Therapy Reduce Relapse Rates of Depression After ECT? A Preliminary Study
Fenton, L., Fasula, M., Ostroff, R., & Sanacora, G. (2006) · The Journal of ECT · doi:10.1097/01.yct.0000235201.42287.b4 · Cited by 41
Self-citationPryazhnikov, E., Mugantseva, E., Casarotto, P., Kolikova, J., Fred, S. M., Toptunov, D., Afzalov, R., Hotulainen, P., Voikar, V., Terry-Lorenzo, R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24933-8 · Cited by 41
Fortress, A. M., Smith, I. M., & Pang, K. C. H. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.009 · Cited by 38
Psychiatric Practice Patterns and Barriers to the Adoption of Esketamine
Wilkinson, S. T., Howard, D. H., & Busch, S. H. (2019) · JAMA · doi:10.1001/jama.2019.10728 · Cited by 35
Self-citationRychlik, M., Bollen, E., & Ryguła, R. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4497-1 · Cited by 32
Toward specific ways to combine ketamine and psychotherapy in treating depression
Hasler, G. (2020) · CNS Spectrums · doi:10.1017/s1092852919001007 · Cited by 29
Sustained Improvement of Negative Self-Schema After a Single Ketamine Infusion: An Open-Label Study
Hasler, G., Suker, S., Schoretsanitis, G., & Mihov, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00687 · Cited by 20
Paredes, D., Silva, J. D., & Morilak, D. A. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy080 · Cited by 5
Research works printed but not linked: 1
- 10.1037/0022-006x.69.6.914 · doi:10.1037/0022-006x.69.6.914 · Paper page
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Self-citationKetamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
“Pilot studies have described bene fi cial effects where ketamine has been combined with CBT [61] and a digital intervention.”
BackgroundGrabski, M., McAndrew, A., Lawn, W., Marsh, B., Raymen, L., Stevens, T., Hardy, L., Warren, F., Bloomfield, M., Borissova, A., et al. (2022) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2021.21030277 · Cited by 175
Psychedelic-Assisted Psychotherapy—A Systematic Review of Associated Psychological Interventions
Cavarra, M., Falzone, A., Ramaekers, J. G., Kuypers, K. P. C., & Mento, C. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.887255 · Cited by 171
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“A recent follow-up study randomized 28 patients who had achieved response after six ketamine infusions to receive either CBT or treatment as usual [67].”
BackgroundInfluential
Metadata
- Authors
- Wilkinson, S. T., Rhee, T. G., Joormann, J., Webler, R., Ortiz Lopez, M., Kitay, B., Fasula, M., Elder, C., Fenton, L., & Sanacora, G.
- Affiliations
- Yale University (US)
- University of Minnesota (US)
- Emory University (US)
- ORCID
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2021
- Volume
- 90
- Issue
- 5
- Pages
- 318-327
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W3176790550
- Cited by
- 108
- References
- 51
- Citations by year
- 2026: 27 · 2025: 20 · 2024: 21 · 2023: 24 · 2022: 15 · 2021: 1
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R01MH125205)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- treatment-resistant depression, ketamine, cognitive behavioral therapy, rapid-acting antidepressants, cognitive flexibility, depression relapse prevention
- MeSH terms
- Antidepressive Agents, Depression, Major Depressive Disorder, Humans, Ketamine, Cognitive Behavioral Therapy, Treatment Outcome, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.